Cui Tao, Terlecki Ryan
1 Departmet of Urology, Wake Forest School of Medicine, Winston Salem, NC, USA.
Am J Mens Health. 2018 May;12(3):608-611. doi: 10.1177/1557988316642723. Epub 2016 Apr 8.
Chronic testicular pain (CTP) is a complex pain syndrome that is widely variable in presentation and etiology. Many cases of CTP are thought to be associated with neuropathy and recent data suggest an inflammation-mediated process is more common among patients with CTP. Deficiencies in vitamin B12 and testosterone are common in chronic pain syndromes may play a role in CTP. A retrospective review of men treated for CTP by a single provider over a 2-year period was performed. Patients with serum screening of testosterone and B12 were selected. Patients with total testosterone below 300 ng/dl, free testosterone below 46 pg/ml, or B12 below 400 pg/ml were deemed deficient and offered repletion. Efficacy of treatment was measured based on patient report with a minimum follow-up of either 3 months or resolution of pain symptoms. One hundred and fifty-four (154) men with CTP were identified, with 125 assessed for testosterone and B12 levels. Of these, 95 patients (76%) were deemed deficient. Fifty-six (56) patients elected to receive B12/testosterone replacement. In patients with sufficient follow-up, 24 patients (65%) reported significant improvement of symptoms, 6 patients (16%) reported some improvement, and 7 patients (19%) reported no improvement. The prevalence of testosterone and B12 deficiencies in this study is much higher than that reported for the general population. In addition, when chemical deficiencies were corrected, greater than 80% of patients with sufficient follow-up reported some improvement in pain. This suggests that screening of B12 and testosterone should be incorporated into the assessment of patients with CTP.
慢性睾丸疼痛(CTP)是一种复杂的疼痛综合征,其表现和病因差异很大。许多CTP病例被认为与神经病变有关,最近的数据表明,炎症介导的过程在CTP患者中更为常见。维生素B12和睾酮缺乏在慢性疼痛综合征中很常见,可能在CTP中起作用。对一位医生在两年内治疗的CTP男性患者进行了回顾性研究。选择进行睾酮和B12血清筛查的患者。总睾酮低于300 ng/dl、游离睾酮低于46 pg/ml或B12低于400 pg/ml的患者被视为缺乏,并给予补充治疗。根据患者报告评估治疗效果,最短随访时间为3个月或疼痛症状消失。共确定了154例CTP男性患者,其中125例进行了睾酮和B12水平评估。其中,95例患者(76%)被视为缺乏。56例患者选择接受B12/睾酮替代治疗。在有足够随访时间的患者中,24例患者(65%)报告症状有显著改善,6例患者(16%)报告有一些改善,7例患者(19%)报告无改善。本研究中睾酮和B12缺乏的患病率远高于一般人群报告的患病率。此外,当纠正化学缺乏时,超过80%有足够随访时间的患者报告疼痛有一定改善。这表明,在对CTP患者进行评估时应纳入B12和睾酮的筛查。